Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 387, Issue 10031, 2016, Pages 1921-1927

  Villiger, Peter M ^a   Adler, Sabine ^a   Kuchen, Stefan ^a   Wermelinger, Felix ^a   Dan, Diana ^a   Fiege, Veronika ^a   Bütikofer, Lukas ^a   Seitz, Michael ^a   Reichenbach, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CALCIUM; COLECALCIFEROL; GLUCOCORTICOID; IBANDRONIC ACID; PANTOPRAZOLE; PLACEBO; PREDNISOLONE; TOCILIZUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYST; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GIANT CELL ARTERITIS; HUMAN; HYPERGLYCEMIA; INFECTION; MAGNETIC RESONANCE ANGIOGRAPHY; MAINTENANCE THERAPY; MALE; MUSCULOSKELETAL DISEASE; MYOPATHY; NEW ONSET GIANT CELL ARTERITIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RECURRENT GIANT CELL ARTERITIS; REMISSION; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SURVIVAL TIME; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELL ARTERITIS; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PREDNISOLONE; TREATMENT OUTCOME;

EID: 84959451366     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00560-2     Document Type: Article

References (26)

1. GG Hunder Epidemiology of giant-cell arteritis Cleve Clin J Med 69 suppl 2 2002 SII79 SII82
2. C Nordborg, H Johansson, V Petursdottir, E Nordborg The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population Rheumatology (Oxford) 42 2003 549 552
3. O Baldursson, K Steinsson, J Björnsson, JT Lie Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis Arthritis Rheum 37 1994 1007 1012
4. M Sonnenblick, G Nesher, Y Friedlander, A Rubinow Giant cell arteritis in Jerusalem: a 12-year epidemiological study Br J Rheumatol 33 1994 938 941
5. CM Weyand, JJ Goronzy Clinical practice. Giant-cell arteritis and polymyalgia rheumatica N Engl J Med 371 2014 50 57
6. GS Hoffman, MC Cid, KE Rendt-Zagar the Infliximab-GCA Study Group Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial Ann Intern Med 146 2007 621 630
7. R Seror, G Baron, E Hachulla et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial Ann Rheum Dis 73 2014 2074 2081
8. JA Jover, C Hernández-García, IC Morado, E Vargas, A Bañares, B Fernández-Gutiérrez Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial Ann Intern Med 134 2001 106 114
9. AD Mahr, JA Jover, RF Spiera et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis Arthritis Rheum 56 2007 2789 2797
10. D Emilie, E Liozon, MC Crevon et al. Production of interleukin 6 by granulomas of giant cell arteritis Hum Immunol 39 1994 17 24
11. NE Roche, JW Fulbright, AD Wagner, GG Hunder, JJ Goronzy, CM Weyand Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis Arthritis Rheum 36 1993 1286 1294
12. J Hernández-Rodríguez, M Segarra, C Vilardell et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis Rheumatology (Oxford) 43 2004 294 301
13. KS van der Geest, WH Abdulahad, A Rutgers et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica Rheumatology (Oxford) 54 2015 1397 1402
14. S Yokota, T Imagawa, M Mori et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan J Rheumatol 41 2014 759 767
15. C Iking-Konert, U von Hinüber, C Richter et al. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany Rheumatology (Oxford) 2015 10.1093/rheumatology/kev372 published online Oct 29.
16. M Mihara, K Kasutani, M Okazaki et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Int Immunopharmacol 5 2005 1731 1740
17. S Unizony, L Arias-Urdaneta, E Miloslavsky et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica Arthritis Care Res (Hoboken) 64 2012 1720 1729
18. J Loricera, R Blanco, JL Hernández et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients Semin Arthritis Rheum 44 2015 717 723
19. F Oliveira, RR Butendieck, WW Ginsburg, K Parikh, A Abril Tocilizumab, an effective treatment for relapsing giant cell arteritis Clin Exp Rheumatol 32 suppl 82 2014 S76 S78
20. M Seitz, S Reichenbach, HM Bonel, S Adler, F Wermelinger, PM Villiger Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series Swiss Med Wkly 141 2011 w13156
21. GG Hunder, DA Bloch, BA Michel et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis Arthritis Rheum 33 1990 1122 1128
22. J Loricera, R Blanco, S Castañeda et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review Clin Exp Rheumatol 32 suppl 82 2014 S79 S89
23. N Nishimoto, N Miyasaka, K Yamamoto, S Kawai, T Takeuchi, J Azuma Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study Ann Rheum Dis 68 2009 1580 1584
24. T Gout, AJ Ostör, MK Nisar Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review Clin Rheumatol 30 2011 1471 1474
25. J Pfeil, J Grulich-Henn, D Wenning, T Breil, P Günther, T Lutz Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab Rheumatology (Oxford) 53 2014 1713 1714
26. JR Curtis, F Xie, L Chen et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients Arthritis Rheum 63 2011 346 351